The 2022 guidance for the first time makes active surveillance the recommended treatment for select patients with favorable intermediate-risk Gleason 3+4 prostate cancer.
/PRNewswire/ Today, the American Urological Association (AUA), in partnership with the American Society for Radiation Oncology (ASTRO), released the 2022.